DXCM Stock Movement Summary Dexcom stock rallied following several key announcements: Q4 Earnings Results: The company beat Wall Street estimates for fourth-quarter earnings and revenues, driven by robust demand for its continuous glucose monitoring systems. Financial Performance: 2025 revenue reached $4.66 billion, a 16% year-over-year increase. Net income was $836.3 million, compared to $576.2 million in 2024. 2026 Guidance: Dexcom affirmed FY2026 sales guidance of $5.160B-$5.250B, representing 11%-13% revenue growth, supported by G7 15 Day rollout and international expansion. Medicare Coverage Expansion: CEO Jake Leach announced the company expects CMS to propose expanded Medicare coverage for Type 2 diabetes patients who don't take insulin in the first half of 2026. A trial readout is planned for mid-2026. This expansion could provide access to nearly 12 million additional people. Product Innovation: Dexcom announced AI-enabled features for its Stelo glucose
Read full analysisDXCM Stock Movement Summary Dexcom stock rallied following several key announcements: Q4 Earnings Results: The company beat Wall Street estimates for fourth-quarter earnings and revenues, driven by robust demand for its continuous glucose monitoring systems. Financial Performance: 2025 revenue reached $4.66 billion, a 16% year-over-year increase. Net income was $836.3 million, compared to $576.2 million in 2024. 2026 Guidance: Dexcom affirmed FY2026 sales guidance of $5.160B-$5.250B, representing 11%-13% revenue growth, supported by G7 15 Day rollout and international expansion. Medicare Coverage Expansion: CEO Jake Leach announced the company expects CMS to propose expanded Medicare coverage for Type 2 diabetes patients who don't take insulin in the first half of 2026. A trial readout is planned for mid-2026. This expansion could provide access to nearly 12 million additional people. Product Innovation: Dexcom announced AI-enabled features for its Stelo glucose
Dexcom makes continuous glucose monitoring (CGM) systems used by people with diabetes to track blood sugar levels in real time without finger pricks. The company generated $4.66 billion in 2025 revenue and is expanding into broader metabolic health with its Stelo consumer product. Today's rally was driven by a Q4 earnings beat and the company's push to expand Medicare coverage to millions of Type 2 diabetes patients who don't use insulin.